<DOC>
	<DOC>NCT00569036</DOC>
	<brief_summary>This is a Phase 1 dose escalation study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of BMS-754807 in patients with advanced or metastatic solid tumors. In addition, the study is expected to identify the recommended dose or dose range of BMS-754807 for Phase 2 studies</brief_summary>
	<brief_title>Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Advanced or Metastatic Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Subjects with advanced or metastatic solid tumors for whom the standard of care is ineffective or inappropriate ECOG performance status 01 at least 4 weeks between surgery or last dose prior anticancer therapy symptomatic brain metastases any disorder or dysregulation of glucose homeostasis {e.g. diabetes) uncontrolled or significant cardiovascular disease inadequate bone marrow, liver or kidney function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Advanced or Metastatic Solid Tumors or Neoplasms</keyword>
</DOC>